Editor’s Note: Prostate cancer is the most common malignant tumor of the male urinary reproductive system. Compared to developed countries, China has a higher proportion of late-stage prostate cancer patients at diagnosis, resulting in poorer prognosis. In recent years, there have been rapid advancements in prostate cancer research. Therefore, developing diagnosis and treatment guidelines tailored to China based on the latest evidence-based medicine is crucial for the early diagnosis, treatment, and prognosis of Chinese prostate cancer patients. As the 2024 CSCO Guidelines Conference approaches, “Oncology Frontier” invited Prof. Dingwei Ye, Chair of the CSCO Prostate Cancer Committee and a professor at Fudan University Cancer Hospital, to discuss the guidelines.
Oncology Frontier: The “CSCO Prostate Cancer Diagnosis and Treatment Guidelines” are one of the authoritative guidelines in the field of prostate cancer in China, significantly contributing to the standardized diagnosis and treatment of prostate cancer in China. As the head of the guideline writing team, can you briefly introduce the characteristics of these guidelines, considering the increasing burden of prostate cancer in China?
Prof. Dingwei Ye: Compared to Western and developed Asian countries (like Japan), the incidence of prostate cancer in China is not particularly high. However, due to the large population base and the aging population, the incidence of prostate cancer has been rapidly increasing in recent years. Additionally, the high mortality rate due to late-stage diagnosis at initial presentation in China highlights the need for early screening, diagnosis, and treatment. The Chinese Cancer Report shows that in 2022, there were approximately 134,000 new cases of prostate cancer and about 47,500 deaths . The incidence and mortality rates have been continuously rising, ranking sixth and seventh among cancers affecting Chinese men, respectively . Two statistics are particularly alarming: the mortality-to-incidence ratio (MIR) of prostate cancer in China is about 0.337, higher than the 0.164 in the United States. Moreover, the MIR for prostate cancer is higher than that for breast cancer in China (0.185) and the United States (0.153). Previously, prostate cancer was considered an “indolent” cancer, but these figures indicate that it requires significant attention in China.
As we all know, with the joint efforts of 18 core members of the guideline writing team and all committee members, the “CSCO Prostate Cancer Diagnosis and Treatment Guidelines” have become one of the most important and authoritative reference guides for prostate cancer in China. It is highly concise, academically focused, and up-to-date, gaining increasing recognition from peers. It is also lightweight and portable, making it easy to quickly reference, and is widely used by urologists and healthcare professionals in clinical practice. I believe this guideline has the following characteristics:
1. It is an up-to-date guideline.
This guideline is updated annually to ensure that the latest and most advanced evidence-based medical evidence, both internationally and domestically, is included. We are diligent and dedicated, completing the annual updates without fail.
2. It is a guideline based on the clinical practice of prostate cancer in China.
We are very proud that this guideline extensively references research and evidence from Chinese experts and scholars based on the Chinese population. While aligning with international standards, we focus on local clinical practice in China, striving to create a guideline truly suitable for Chinese prostate cancer patients. I take this opportunity to thank all the scholars dedicated to prostate cancer research in China. Their relentless exploration has allowed evidence-based medical evidence based on the Chinese population to profoundly influence and guide changes in clinical practice for prostate cancer treatment in China.
3. It is a guideline that embodies the wisdom of multidisciplinary experts.
Another significant feature of the CSCO Prostate Cancer Diagnosis and Treatment Guidelines is the integration of multidisciplinary experts in its writing. Prostate cancer is not solely the concern of urologists; it also requires the involvement of medical oncologists, radiologists, pathologists, and nuclear medicine experts. Using a multidisciplinary team (MDT) approach to treat prostate cancer is crucial for improving the five-year survival rate of prostate cancer patients in China.
▌References:
1. Han B, Zheng R, Zeng H, et al. Cancer incidence and mortality in China, 2022. Journal of the National Cancer Center, 2024.
Prof. Dingwei Ye
– Vice President, Fudan University Cancer Hospital
– Leader in Urology
– Chief Expert in Urologic Oncology MDT
– Director, Shanghai Institute of Urologic Oncology
– Director, Fudan University Prostate Cancer Institute
– Chairman, Chinese Anti-Cancer Association (CACA) Male Reproductive System Tumors Committee (CACA-GO)
– Chairman, CSCO Prostate Cancer Committee
– Chairman, Urology Committee, Chinese Primary Health Care Foundation
– Former Chairman, CACA Urologic Oncology Committee (CACA-GU)
– Vice Leader, Oncology Group, Chinese Urological Association (CUA) and Chairman, Chinese Prostate Cancer Consortium (CPCC)
– Vice Chairman, CSCO Urothelial Cancer Committee
– Vice Chairman, CSCO Kidney Cancer Committee and CSCO Immunotherapy Committee
– Chairman, Urologic Oncology Committee, Shanghai Anti-Cancer Association
– Deputy Leader, NCCN Kidney Cancer Treatment Guidelines China Edition Writing Team
– Member, NCCN Prostate Cancer, Kidney Cancer, and Bladder Cancer Asia Consensus Expert Committee
– Member, St. Gallen Advanced Prostate Cancer Consensus Expert Committee
– Incoming Chairman, Asia-Pacific Prostate Society (APPS)
– Vice President, Asia-Pacific Cryosurgery Society
– Principal Investigator for over 60 national and provincial research grants, published 676 papers (402 in SCI journals), authored and translated 9 books, holds 32 patents. Received multiple awards including Shanghai Science and Technology Progress First Prize (twice), Ministry of Education Science and Technology Achievement First and Second Prizes, Shanghai Medical Science First Prize, and CACA Science and Technology Second Prize. Recognized as an Outstanding Mid-Career Expert by the National Health Commission, awarded the Wu Jieping Urology Medicine Prize, WuXi AppTec Life Chemistry Research Prize, Shanghai Leading Talent, Shanghai Outstanding Discipline Leader, Shanghai Craftsman, and National Advanced Worker in the Health System, and enjoys special government allowances from the State Council.
